Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1. Considerations with surgery, radiation, rate of relapse
2. Adjuvant chemotherapy
3. Adjuvant immune checkpoint inhibition
4. Emerging neoadjuvant trial

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Great summary of differences in 7th and 8th staging editions (misspoke in episode as radiopedia):

https://radiologyassistant.nl/chest/lung-cancer/tnm-classification-8th-edition

1.           Spicer J et al.  JCO. 2023;41(16_suppl):8521-8521. doi:10.1200/JCO.2023.41.16_SUPPL.8521

2.           Wakelee H et al. NEJM. Published online June 3, 2023. doi:10.1056/NEJMOA2302983

3.           Forde PM et al. NEJM. 2022;386(21):1973-1985. doi:10.1056/NEJMOA2202170

4.           Winton T et al. NEJM. 2005;352(25):2589-2597. doi:10.1056/NEJMOA043623

5.           Stewart et al. BMJ. 1995;311(7010):899-909. doi:10.1136/BMJ.311.7010.899

6.           Arriagada R et al. NEJM. 2004;350(4):351-360. doi:10.1056/NEJMOA031644

7.           Felip E et al. The Lancet. 2021;398(10308):1344-1357. doi:10.1016/S0140-6736(21)02098-5

8.           Strauss GM et al. J Clin Oncol. 2008;26(31):5043-5051. doi:10.1200/JCO.2008.16.4855

9.        Pignon JP et al. JCO. 2008;26(21):3552-3559. doi:10.1200/JCO.2007.13.9030

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. EGFR inhibitors
2. ALK inhibitors
3. Less common molecular targets
4. Role of KRAS inhibitors and evidence for sotorasib

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           de Langen AJ et al. The Lancet. 2023;401(10378):733-746. doi:10.1016/S0140-6736(23)00221-0

2.           Wolf J et al. NEJM. 2020;383(10):944-957. doi:10.1056/NEJMOA2002787/

3.           Felip E et al. Annals of Oncology. 2021;32(5):620-630. doi:10.1016/j.annonc.2021.02.012

4.           Cho BC et al. J Thorac Oncol. 2017;12(9):1357-1367. doi:10.1016/J.JTHO.2017.07.005

5.           Peters S et al. NEJM. 2017;377(9):829-838. doi:10.1056/NEJMOA1704795/

6.           Solomon BJ et al. JCO. 2018;36(22):2251-2258. doi:10.1200/JCO.2017.77.4794

7.           Solomon BJ et al. NEJM. 2014;371(23):2167-2177. doi:10.1056/NEJMOA1408440

8.           Yang JCH et al. Lancet Oncol. 2015;16(2):141-151. doi:10.1016/S1470-2045(14)71173-8

9.           Soria JC et al. NEJM. 2018;378(2):113-125. doi:10.1056/NEJMOA1713137/

10.        Ramalingam SS et al. NEJM. 2020;382(1):41-50. doi:10.1056/NEJMOA1913662/

11.        Zhang SS et al. Lung Cancer: Targets and Therapy. 2023;14:27. doi:10.2147/LCTT.S403461

12.        Olivier T et al. Transl Oncol. 2023;28:101591. doi:10.1016/J.TRANON.2022.101591

13.        Papadimitrakopoulou VA, et al. Ann Oncol. 2020;31(11):1536-1544. doi:10.1016/J.ANNONC.2020.08.2100

14.        Fukuoka M et al. J Clin Oncol. 2011;29(21):2866-2874. doi:10.1200/JCO.2010.33.4235

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Evidence to support platinum doublets
2. The tale of pemetrexed
3. Immune checkpoint inhibitors alone and in combination
4. Second Line, approach in progression

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Paz-Ares L et al.  Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0

2.           Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231

3.           Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009

4.           Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774

5.           Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865

6.           Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/

7.           Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232

8.           Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3

9.           Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102

10.        Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375

11.        Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470

12.        Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196

13.        Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Presentation and Work-up
2. Staging and how to memorize staging algorithms
3. SVC Syndrome, an oncologic emergency
4. Variations by histology and molecular mutations

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Patterns of recurrence and approach to stage IV disease
2. Immunotherapy and BRAF/MEK considerations
3. Cross trial comparisons
4. Later line and emerging therapies for advanced melanoma

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Atkins MB et al. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763

2.           Robert C et al. NEJM. 2019;381(7):626-636. doi:10.1056/NEJMOA1904059/

3.           Lebbé C et al. J Clin Oncol. 2019;37(11):867-875. doi:10.1200/JCO.18.01998

4.           Wolchok JD et al. J Clin Oncol. 2022;40(2):127-137. doi:10.1200/JCO.21.02229

5.           Larkin J et al. NEJM. 2015;373(1):23-34. doi:10.1056/NEJMOA1504030

6.           Nathan P et al. NEJM. 2021;385(13):1196-1206. doi:10.1056/NEJMOA2103485

7.           Sarnaik AA et al. J Clin Oncol. 2021;39(24):2656-2666. doi:10.1200/JCO.21.00612

8.           Tawbi HA  et al. NEJM. 2022;386(1):24-34. doi:10.1056/NEJMOA2109970

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Background, staging and work-up of regional melanoma
2. Evidence for adjuvant and neoadjuvant immunotherapy
3. Adjuvant BRAF/MEK inhibitor 
4. Considerations for stage IIB/IIC disease

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Patel SP et al. NEJM. 2023;388(9):813-823. doi:10.1056/NEJMOA2211437/

2.           Weber J et al. NEJM. 2017;377(19):1824-1835. doi:10.1056/NEJMOA1709030

3.           Eggermont AMM et al. NEJM. 2018;378(19):1789-1801. doi:10.1056/NEJMOA1802357

4.           Lao CD. Am Soc Clin Oncol Educ Book. 2022;42(42):1-7. doi:10.1200/EDBK_351153

5.           Faries MB et al.  NEJM. 2017;376(23):2211-2222. doi:10.1056/NEJMOA1613210/

6.           Morton DL et al. NEJM. 2014;370(7):599-609. doi:10.1056/NEJMOA1310460/

7.           Welch HG et al. NEJM. 2021;384(1):72-79. doi:10.1056/NEJMSB2019760/

8.           Michielin O et al.   Ann Oncol. 2019;30(12):1884-1901. doi:10.1093/ANNONC/MDZ411

9.           Luke JJ  et al. Lancet. 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1

10.        Long G V  et al. NEJM. 2017;377(19):1813-1823. doi:10.1056/NEJMOA1708539/

11.        Dummer R  et al. NEJM. 2020;383(12):1139-1148. doi:10.1056/NEJMOA2005493/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. History of Immunotherapy
2. Modern immune checkpoint inhibitors (ICIs)
3. Unique considerations with ICIs
4. Immune related adverse events and immortal time bias in observational studies

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.          Yadav K, Lewis RJ. JAMA. 2021;325(7):686-687. doi:10.1001/JAMA.2020.9151

2.           Holstead RG et al. Melanoma Res. 2021;31(3):258-263. doi:10.1097/CMR.0000000000000736

3.           Kartolo A et al. J Immunother. 2021;44(4):167-174. doi:10.1097/CJI.0000000000000360

4.           Dolladille C et al. JAMA Oncol. 2020;6(6):865-871. doi:10.1001/JAMAONCOL.2020.0726

5.           Mahmood SS et al. J Am Coll Cardiol. 2018;71(16):1755-1764. doi:10.1016/J.JACC.2018.02.037

6.           Coley WB. Proc R Soc Med. 1910;3(Surg Sect):1. doi:10.1177/003591571000301601

7.           Larkin J  et al.  NEJM. 2019;381(16):1535-1546. doi:10.1056/NEJMOA1910836/

8.           Wolchok JD  et al. Lancet Oncol. 2010;11(2):155-164. doi:10.1016/S1470-2045(09)70334-1

9.           Hodi FS et al. NEJM. 2010;363(8):711-723. doi:10.1056/NEJMOA1003466/SUPPL_FILE/

10.        Brahmer J et al. JCO. 2018;36(17):1714-1768 doi:10.1200/JCO.2017.77.6385

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. BRCA 1/2 genes and relation to malignancy
2. Family history taking and identifying patients for genetic testing
3. Risk reduction strategies for breast and ovarian cancer
4. Systemic therapy considerations in BRCA positive breast cancer

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Litton JK et al. NEJM. 2018;379(8):753-763. doi:10.1056/NEJMOA1802905/

2.           Geyer CE et al. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159

3.           Robson M et al. NEJM. 2017;377(6):523-533. doi:10.1056/NEJMOA1706450/

4.           Tutt ANJ et al. NEJM. 2021;384(25):2394-2405. doi:10.1056/NEJMOA2105215/

5.           Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes | ESMO. Accessed March 13, 2023. https://www.esmo.org/guidelines/guidelines-by-topic/hereditary-syndromes/risk-reduction-screening-hereditary-breast-ovarian-cancer-syndromes

6.           Breast Cancer Screening for Women at High Risk – Cancer Care Ontario. Accessed March 13, 2023. https://www.cancercareontario.ca/en/guidelines-advice/cancer-continuum/screening/breast-cancer-high-risk-women

7.           Chiarelli AM et al. JCO. 2014;32(21):2224-2230. doi:10.1200/JCO.2013.52.8331

8.           Detection, Prevention, and Risk Reduction. Accessed March 13, 2023. https://www.nccn.org/guidelines/category_2

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Clinical considerations
2. Neoadjuvant and adjuvant regimens
3. Immunotherapy in localized and metastatic disease
4. Later line options in metastatic setting

*Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those that are node positive.

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.           Masuda N et al. NEJM. 2017;376(22):2147-2159. doi:10.1056/NEJMOA1612645/

2.           Zaheed M et al. Cochrane. 2019;2019(2). doi:10.1002/14651858.CD012873.PUB2/

3.           Cortes J et al. The Lancet. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9

4.           Cortes J et al. NEJM. 2022;387(3):217-226. doi:10.1056/NEJMOA2202809/

5.           Miles D  et al. Ann Oncol. 2021;32(8):994-1004. doi:10.1016/j.annonc.2021.05.801

6.           Emens LA  et al. Ann Oncol. 2021;32(8):983-993. doi:10.1016/j.annonc.2021.05.355

7.           Schmid P  et al. NEJM. 2022;386(6):556-567. doi:10.1056/NEJMOA2112651/

8.           Schmid P  et al. NEJM. 2020;382(9):810-821. doi:10.1056/NEJMOA1910549/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Role of adjuvant HER-2 Agents and during of therapy
2. Chemotherapy backbone considerations
3. Pathologic complete response
4. Neoadjuvant systemic therapy and response modified approach

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/

2.von Minckwitz G et al. NEJM. 2017;377(2):122-131. doi:10.1056/NEJMOA1703643/

3.Slamon D et al.. NEJM. 2011;365(14):1273-1283. doi:10.1056/NEJMOA0910383

4.Piccart M et al. JCO. 2021;39(13):1448-1457. doi:10.1200/JCO.20.01204

5.Martin M  et al. Lancet Oncol. 2017;18(12):1688-1700. doi:10.1016/S1470-2045(17)30717-9

6.von Minckwitz G et al. NEJM. 2019;380(7):617-628. doi:10.1056/NEJMOA1814017/

7.Gianni L et al. Lancet Oncol. 2014;15(6):640-647. doi:10.1016/S1470-2045(14)70080-4

8.Symmans WF et al.. J Clin Oncol. 2017;35(10):1049-1060. doi:10.1200/JCO.2015.63.1010

9.Gianni L et al. Lancet Oncol. 2016;17(6):791-800. doi:10.1016/S1470-2045(16)00163-7

10.Gianni L et al. Lancet Oncol. 2012;13(1):25-32. doi:10.1016/S1470-2045(11)70336-9

11.Gilboa S et al. Eur J Cancer. 2021;153:190-202. doi:10.1016/J.EJCA.2021.04.044

12.Tolaney SM et al. NEJM. 2015;372(2):134-141. doi:10.1056/NEJMOA1406281/

13.Cameron D et al. Lancet. 2017;389(10075):1195-1205. doi:10.1016/S0140-6736(16)32616-2

14.Earl HM et al. Lancet. 2019;393(10191):2599-2612. doi:10.1016/S0140-6736(19)30650-6

15.Pivot X et al. Lancet. 2019;393(10191):2591-2598. doi:10.1016/S0140-6736(19)30653-1

16.Perez EA et al. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730

17.Romond EH et al. NEJM. 2005;353(16):1673-1684. doi:10.1056/NEJMOA052122/

18.Ennis S et al.. NEJM. 2001;344(11):783-792. doi:10.1056/NEJM200103153441101

19.Hudis CA. NEJM. 2007;357(1):39-51. doi:10.1056/NEJMRA043186

20.Slamon DJ et al. Science. 1987;235(4785):182-191. doi:10.1126/SCIENCE.3798106

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology